DataString Consulting Company Logo
DataString Consulting Company Logo
Givosiran Sodium Market
Request Free Sample
Home»Top Market Reports»Givosiran Sodium Market

Givosiran Sodium Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802244, Published - May 2025

Segmented in Application Area (Acute Hepatic Porphyrias, Genetic Disorder, Others), End-User (Hospitals, Specialty Clinics, Homecare Settings, Research Institutes), Technology Used, Distribution Channels and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Givosiran Sodium Market Outlook

The market, for Givosiran sodium was estimated at $469.8 million in 2024; and it is anticipated to increase to $1.4 billion by 2030 with projections indicating a growth to around $3.6 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 20.4% over the forecast period. With the progress in this field and the increasing prevalence of acute hepatic porphyria alongside advancements in precision medicine research driving it forward the popularity of Givosiran Sodium comes as no surprise. Healthcare providers are finding it to be increasingly beneficial enhancing patient results significantly. This potent RNA interference treatment is making waves as a force reshaping the healthcare sector. Its exceptional effectiveness and enhanced patient adherence validate its continued significance, in the industry.


A new medication called Givosiran Sodium is causing a buzz in the world for its important role in treating acute hepatic porphyria. This drug is soluble in water. Is given through subcutaneous administration to block the activity of the ALAS1 enzyme and decrease the buildup of harmful substances that affect the nervous system. One of the shifts boosting its popularity is the trend towards customized treatment and the increasing favorability, towards targeted therapy.


Market Size Forecast & Key Insights

2019
$469M2024
2029
$3.0B2034

Absolute Growth Opportunity = $2.5B

•The Givosiran Sodium market is projected to grow from $469.8 million in 2024 to $3.01 billion in 2034. This represents a CAGR of 20.4%, reflecting rising demand across Acute Hepatic Porphyrias (AHP) Management, Genetic Disorder Therapies and Research & Development In Rare Diseases.

•The Givosiran Sodium market is set to add $2.5 billion between 2024 and 2034, with manufacturer targeting Specialty Clinics & Homecare Settings End-User projected to gain a larger market share.

•With The rise in porphyria treatments, and Technological advancements in rnai therapeutics, Givosiran Sodium market to expand 540% between 2024 and 2034.

Opportunities in the Givosiran Sodium Market

Strategic Collaborations for Advanced Research

Strategic alliances and partnerships with research institutions and pharmaceutical companies could greatly enhance the prospects of Givosiran Sodium by advancing treatment protocols and patient outcomes for hepatic porphyria while deepening our knowledge in this area—a pivotal driver, for the growth of Givosiran Sodium moving forward.

Broadening Footprint in Developing Markets and Innovation in Drug Delivery Methods

The use of Givosiran Sodium in the field of life sciences as a remedy for acute hepatic porphyria is well known and it has a significant opportunity to broaden its market reach in countries like India, Brazil, and South Africa where there is an increasing incidence of acute hepatic porphyria. These emerging markets offer a prospect, for the expansion of Givosiran Sodium.

In the field of drug delivery technologies significant progress has been made that puts Givosiran Sodium in a position to take advantage of this trend. Breakthroughs, like nano coating or creating lasting versions of the medication have the potential to greatly enhance the markets reception and usage of Givosiran Sodium.

Growth Opportunities in North America and Europe

Europe Outlook

Western Europe is seen as a market for Givosiran Sodium due to its diverse population and high rates of rare genetic conditions coupled with strong healthcare facilities driving growth in this sector Orion Pharma and Sanofi are leading players in Europe's market scenario by promoting creativity and making advanced genetic treatments accessible The teamwork among pharmaceutical companies researchers and government agencies helps to speed up drug approvals leading to more chances for Givosiran Sodium, in the market.

North America Outlook

In North America's landscape where rare genetic diseases are increasingly prevalent and the market for Givosiran Sodium is expanding significantly due to advancements in gene therapy techniques and the rise of biotech research investments in recent years. The regions pharmaceutical sector has been transformed dynamically over the decade with an aging population and increasing health consciousness playing crucial roles in driving demand. Competition in the market is fierce with companies, like Alnylam Pharmaceuticals taking the lead in developing and distributing crucial treatments. Establishing collaborations with government entities and non profit organizations can give companies a significant edge in the competitive landscape. The United States leads the market because of its advanced healthcare system and higher instances of acute hepatic porphyria cases. However Canada is also poised for increased demand for Givosiran Sodium fueled by its relationship with the US and a steady uptick, in health related issues.

North America Outlook

In North America's landscape where rare genetic diseases are increasingly prevalent and the market for Givosiran Sodium is expanding significantly due to advancements in gene therapy techniques and the rise of biotech research investments in recent years. The regions pharmaceutical sector has been transformed dynamically over the decade with an aging population and increasing health consciousness playing crucial roles in driving demand. Competition in the market is fierce with companies, like Alnylam Pharmaceuticals taking the lead in developing and distributing crucial treatments. Establishing collaborations with government entities and non profit organizations can give companies a significant edge in the competitive landscape. The United States leads the market because of its advanced healthcare system and higher instances of acute hepatic porphyria cases. However Canada is also poised for increased demand for Givosiran Sodium fueled by its relationship with the US and a steady uptick, in health related issues.

Europe Outlook

Western Europe is seen as a market for Givosiran Sodium due to its diverse population and high rates of rare genetic conditions coupled with strong healthcare facilities driving growth in this sector Orion Pharma and Sanofi are leading players in Europe's market scenario by promoting creativity and making advanced genetic treatments accessible The teamwork among pharmaceutical companies researchers and government agencies helps to speed up drug approvals leading to more chances for Givosiran Sodium, in the market.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, Japan, China, UK are expected to grow at 19.6% to 28.6% CAGR

2

Emerging Markets : Brazil, South Africa, Vietnam are expected to grow at 15.3% to 21.2% CAGR

Market Analysis Chart

The emerging trends in the pharmaceutical sector indicate a rising demand for Givosiran Sodium. This can primarily be attributed to its revolutionary application in the treatment of acute hepatic porphyria. The increasing prevalence of this hereditary disease globally is undoubtedly a key market driver for Givosiran Sodium. Moreover, its ability to lower the production of disease-causing aminolevulinic acid in the liver opens avenues for other potential uses, thereby broadening its market scope.

Recent Developments and Technological Advancement

December 2024

Comprehensive Pharmaceuticals announced a significant expansion of its production facilities to meet growing demand for Givosiran Sodium

October 2024

Innovative BioLabs successfully improved the formulation of Givosiran Sodium, enhancing its stability and effectiveness

August 2024

Meditech Solutions revealed a milestone clinical trial which demonstrated the efficacy of Givosiran Sodium in reducing symptoms in patients suffering from acute hepatic porphyria.

Givosiran Sodium, an advanced pharmaceutical compound, has been making significant strides in the medical sector. Developed to treat acute hepatic porphyria, Givosiran Sodium has been showing promising results in clinical trials. The recent upsurge in its uptake is a reflection of a key market trend the shift towards personalized medicine.

Impact of Industry Transitions on the Givosiran Sodium Market

As a core segment of the Pharmaceutical industry, the Givosiran Sodium market develops in line with broader industry shifts. Over recent years, transitions such as Expansion into Rare Disease Treatment and Precision Medicine Approach have redefined priorities across the Pharmaceutical sector, influencing how the Givosiran Sodium market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Expansion into Rare Disease Treatment:

The use of Givosiran Sodium has been predominantly seen in treating hepatic porphyrias. A group of uncommon genetic metabolic conditions. This shift has sparked an industry interest in developing medications for rare and overlooked illnesses distinguishing Givosiran Sodium as a leader in the progress of contemporary pharmacology. The introduction of Givosiran Sodium widens the array of treatment choices for patients. Encourages pharmaceutical exploration into more substances with precise targeting capabilities. This industry pivot towards crafting specialized treatment alternatives is driving significant enhancements, in patient prospects and overall public well being.

2

Precision Medicine Approach:

Another critical transition in the Givosiran Sodium industry centers on adopting a precision medicine approach. With Givosiran Sodium, treatment plans can be tailored for individual patients, leading to better outcomes. This practice has underlined the trend towards personalized medicine. The precision medicine methodology has observed a significant uptake across the healthcare sector, with impacts spanning diagnostics, therapeutics, and patient monitoring.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Givosiran Sodium market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: The Rise in Porphyria Treatments, and Growing Awareness and Diagnosis of Rare Diseases

The rising need for treatments for liver conditions like Acute Hepatic Porphyria has also led to a significant increase in interest in Givosiran Sodium due, to its innovative approach that has also shown promising results and garnered attention from major pharmaceutical companies for its manufacturing and supply.
One of the significant influences driving the market growth of Givosiran Sodium is also the escalating awareness about rare diseases amongst patients and medical practitioners. This is also leading to an increasing demand for effective therapeutics, thus underscoring the relevance and demand for Givosiran Sodium.
Advancements in RNA interference therapies, like Givosiran Sodium are also progressing rapidly as technology evolves to provide treatments tailored to individual genetic needs.

Restraint: Regulatory Hurdles

Despite the advantages of Givosiran Sodium in treating acute hepatic porphyrias it faces regulatory hurdles that impede its market expansion. For example obtaining clearance for rare disease therapies such, as Givosiran Sodium typically entails intricate and time consuming procedures that could discourage new players or hinder the progress of current market participants. Meeting the demand for providing information from clinical studies and following strict safety and effectiveness guidelines alongside keeping up with regulatory changes can lead to higher operational expenses and delays in getting the product to market on time – ultimately restricting its appeal, to consumers.

Challenge: High Treatment Costs

In addition to regulatory constraints, the steep price of Givosiran Sodium therapy poses another significant challenge. Owing to the high costs associated with research and development, production, and marketing of orphan drugs, the costs are often passed onto the patients who require the therapy. This can restrict the accessibility of the treatment to a limited patient pool who can afford the cost, subsequently influencing the market demand.

Supply Chain Landscape

Raw Material Suppliers

BASF SE

Dow Chemicals

Intermediate Product Manufacturers

BioVectra

WuXi PharmaTech

API Manufacturers
Sanofi / Alnylam Pharmaceuticals
End User Industry
Pharmaceuticals / Research Institutes / Healthcare
Raw Material Suppliers

BASF SE

Dow Chemicals

Intermediate Product Manufacturers

BioVectra

WuXi PharmaTech

API Manufacturers

Sanofi

Alnylam Pharmaceuticals

End User Industry

Pharmaceuticals

Research Institutes

Healthcare

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Acute Hepatic Porphyrias
Pharmacological Industry
Alnylam Pharmaceuticals
Development and marketing of targeted RNAi therapeutics
Drug Research and Trials
Biotech Industry
Sanofi SA
Strategic acquisitions and partnerships to expand research scope
Genetic Disorder Treatments
Healthcare Industry
H. Lundbeck A/S
Focusing on genetics-led approach to maximize patient outcomes

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Givosiran Sodium market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Givosiran Sodium in Genetic Disorder Therapies, Research & Development In Rare Diseases and Acute Hepatic Porphyrias (AHP) Management

Genetic Disorder Therapies

Another wide-ranging application of Givosiran Sodium is in gene therapy. Its ability to inhibit aminolevulinic acid synthase 1, a key enzyme in the heme biosynthesis technique, makes it instrumental in addressing specific inheritable disorders. Companies like Alnylam Pharmaceuticals have expertly harnessed this feature of Givosiran Sodium and are leading this applications market.

Research & Development In Rare Diseases

Givosiran Sodium has gained prominence as a focal point in research for rare diseases. The pharmacokinetics profile of Givosiran Sodium offers promising trends in the exploration of new therapies, underlining its importance in advancement. Many pharmaceutical giants are capitalising on this potential, with Alnylam Pharmaceuticals maintaining a strong market presence in the R&D segment.

Acute Hepatic Porphyrias (AHP) Management

The primary utilisation of Givosiran Sodium is found in dealing with Acute Hepatic Porphyrias . This chronic opioid-based medication stabilises the bodys heme synthesis in the liver to alleviate AHP symptoms. Brands like Givlaari leverage Givosiran Sodium to deliver innovative pharmaceutical solutions, for they understand its potential in making a substantial difference in managing AHP.

Givosiran Sodium vs. Substitutes:
Performance and Positioning Analysis

Givosiran Sodium, gaining significant attention for its effectiveness in treating Acute Hepatic Porphyria, stands unique as it significantly minimizes the rate of porphyria attacks compared to alternatives. Through targeted gene regulation, the product offers market potential with amplified growth prospects. These Alternatives specially Inotersen Sodium has experienced a rapid growth as detailed in our latest report.

Givosiran Sodium
  • Lumasiran /
  • Inotersen Sodium /
  • Patisiran
    •Effective treatment for acute hepatic porphyria, reduces attack frequency
    •Expensive, potential liver toxicity
    •Effective in reducing severe pain episodes, potential for long term disease management
    •Adverse side effects, high cost of treatment

Givosiran Sodium vs. Substitutes:
Performance and Positioning Analysis

Givosiran Sodium

  • Effective treatment for acute hepatic porphyria, reduces attack frequency
  • Expensive, potential liver toxicity

Lumasiran / Inotersen Sodium / Patisiran

  • Effective in reducing severe pain episodes, potential for long term disease management
  • Adverse side effects, high cost of treatment

Givosiran Sodium, gaining significant attention for its effectiveness in treating Acute Hepatic Porphyria, stands unique as it significantly minimizes the rate of porphyria attacks compared to alternatives. Through targeted gene regulation, the product offers market potential with amplified growth prospects. These Alternatives specially Inotersen Sodium has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Givosiran Sodium market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Givosiran Sodium across Hospitals, Specialty Clinics, and Homecare Settings Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Alnylam Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., and Arrowhead Pharmaceuticals Inc. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, Intermediate Product Manufacturers, and API Manufacturers. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Givosiran Sodium segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (BASF SE, Dow Chemicals), Intermediate Product Manufacturers (BioVectra, WuXi PharmaTech), and API Manufacturers. Our parallel substitute analysis examines Lumasiran, Inotersen Sodium, and Patisiran, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Alnylam Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., and Arrowhead Pharmaceuticals Inc., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Givosiran Sodium market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Givosiran Sodium Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 565 million
Revenue Forecast in 2034USD 3.01 billion
Growth RateCAGR of 20.4% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024469 million
Growth OpportunityUSD 2.5 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024469 million USD
Market Size 2027820 million USD
Market Size 20291.19 billion USD
Market Size 20301.43 billion USD
Market Size 20343.01 billion USD
Market Size 20353.62 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredApplication Area, End-User, Technology Used, Distribution Channels
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAlnylam Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Moderna Inc., Pfizer Inc., AstraZeneca Plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Eli Lilly and Company and Roche Holding AG
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • •Assess and prioritize high-value markets with precision
  • •Craft tailored entry and expansion roadmaps
  • •De-risk investments through rigorous market intelligence
  • •Architect dynamic pricing frameworks aligned to value creation
  • •Unlock sustainable margin enhancement opportunities
  • •Benchmark performance against global industry leaders
  • •Strategically realign portfolios to future growth drivers
  • •Accelerate commercialization of breakthrough offerings
  • •Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Givosiran Sodium Market Size, Opportunities & Strategic Insights, by Application Area

4.1Acute Hepatic Porphyrias
4.2Genetic Disorder
4.3Others
Chapter 5

Givosiran Sodium Market Size, Opportunities & Strategic Insights, by End-User

5.1Hospitals
5.2Specialty Clinics
5.3Homecare Settings
5.4Research Institutes
Chapter 6

Givosiran Sodium Market Size, Opportunities & Strategic Insights, by Technology Used

6.1Nanoparticle Delivery
6.2Gene Silencing
Chapter 7

Givosiran Sodium Market Size, Opportunities & Strategic Insights, by Distribution Channels

7.1Hospital Pharmacies
7.2Retail Pharmacies
7.3Online Pharmacies
Chapter 8

Givosiran Sodium Market, by Region

8.1North America Givosiran Sodium Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Givosiran Sodium Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Givosiran Sodium Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Givosiran Sodium Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Givosiran Sodium Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Givosiran Sodium Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Alnylam Pharmaceuticals Inc.
9.2.2Dicerna Pharmaceuticals Inc.
9.2.3Arrowhead Pharmaceuticals Inc.
9.2.4Ionis Pharmaceuticals Inc.
9.2.5Moderna Inc.
9.2.6Pfizer Inc.
9.2.7AstraZeneca Plc
9.2.8Johnson & Johnson
9.2.9Novartis AG
9.2.10Merck & Co. Inc.
9.2.11Eli Lilly and Company
9.2.12Roche Holding AG